About Astrocyte Pharmaceuticals
Harnessing the Potential of Astrocytes to Treat Brain Injuries and Diseases Astrocyte Pharmaceuticals is developing innovative neuroprotection therapies for Traumatic Brain Injuries (TBI), concussions, stroke, and neurodegenerative disorders Learn More Brain Injuries Brain injuries are a…
Sectors & Market Categories
Company Details
Corporate & Operational Profile
Primary Industry
Biotech & Healthcare
Funding Stage
Series-B+
Global Headquarters
Cambridge, United States
Tracked Since
Oct 1, 2026
Web & Domain Identity
Official Website
astrocytepharma.com
Domain Registered Date
Jun 24, 2014
Social & Network Presence
LinkedIn Corporate
Not linked
Company Milestones & Timeline
- Capital Raise
Raised $9,500,000 · Series-B+
prnewswire.com
- Capital Raise
Raised $9,500,000 · Series-B+
prnewswire.com
- Milestone
X account created (@astrocytepharma)
201 followers
- Milestone
Website domain registered
astrocytepharma.com
Investors & Backers
Angel Star Ventures
Boston Harbor Angels
DeepWork Capital
Dreavent Capital
Dynagrow Capital
MintPharma Capital
National Institute on Drug Abuse (NIDA)
Navis Capital Partners
Sidecar Angels
WaterStart Capital
Funding History
Series-B+
· Sep 30, 2026
$9,500,000 prnewswire.com
Series-B+
· Aug 18, 2023
$9,500,000 prnewswire.com
Founders & Leadership
James D. Lechleiter
Co-Founder and Advisor
Work email & phone locked
Unlock →
Jeffrey Ives
Director
Work email & phone locked
Unlock →
Theodore Liston
Vice President of Research
Work email & phone locked
Unlock →
William S. Korinek
Co-Founder and Chief Executive Officer
Work email & phone locked
Unlock →
Press Coverage & Sources
Recently Funded Biotech & Healthcare Startups
View allVitalls
vitalls.ai
Seed Abu Dhabi, United Arab Emirates · Oct 2026
Hexagon Bio
hexagonbio.com
Series-B+ Oct 2026
RefloDx
reflodx.com
Seed Kaysville, United States · Oct 2026
HeyVoli
heyvoli.com
Pre-Seed Bangalore, India · Oct 2026
CureBay
curebay.com
Series-B+ Bhubaneshwar, India · Oct 2026
4Tissue
4tissue.com
Series-A Ghent, Belgium · Oct 2026